A systematic literature review of methods of incorporating mortality in cost-effectiveness analyses of lipid-lowering therapies

References

• Centers for Disease Control and Prevention, National Center for Health Statistics. FastStats: Health Expenditures [Internet]. FastStats. 2017. https://www.cdc.gov/nchs/fastats/health-expenditures.htm. [Last accessed 11 April 2017].
   Google Scholar
• Gold MR, Seigel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996
   Google Scholar
• Towse A, Pritchard C, Devlin N, editors. Cost-Effectiveness Thresholds: Economic and Ethical Issues. King's Fund and Office of Health Economics; 2002. p 56-68
   Google Scholar
• Neumann PJ, Thorat T, Shi J, et al. The changing face of the cost-utility literature, 1990–2012. Value Health 2015;18:271-7
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation 2017;135:e146-e603
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation 2016;133:e38-e360
   PubMed Web of Science ®Google Scholar
• Casali PG, Bruzzi P, Bogaerts J, et al. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. Ann Oncol 2015;26:300-6
   PubMed Web of Science ®Google Scholar
• Landais P, Daures J-P. Clinical trials, immunosuppression and renal transplantation: new trends in design and analysis. Pediatr Nephrol 2002;17:573-84
   PubMed Web of Science ®Google Scholar
• Sawaya GF, Guirguis-Blake J, LeFevre M, et al. Update on the methods of the US preventive services task force: Estimating certainty and magnitude of net benefit. Ann Intern Med 2007;147:871-5
   PubMed Web of Science ®Google Scholar
• All Wales Therapeutics and Toxicology Centre. AWMSG Secretariat Assessment Report. Rosuvastatin (Crestor®). Penarth, Vale of Glamorgan, Wales Reference number: 1311. 2012
   Google Scholar
• Annemans L, Marbaix S, Webb K, et al. Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the Belgian population. Clin Drug Investig 2010;30:133-42
   PubMed Web of Science ®Google Scholar
• Ara R, Pandor A, Stevens J, et al. Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy? Eur J Prev Cardiol 2012;19:474-83
   PubMed Web of Science ®Google Scholar
• Ara R, Pandor A, Tumur I, et al. Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model. Am J Cardiovasc Drugs 2008;8:419-27
   PubMed Web of Science ®Google Scholar
• Ara R, Pandor A, Tumur I, et al. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries. Clin Ther 2008;30:1508-23
   PubMed Web of Science ®Google Scholar
• Araujo DV, Bahia L, Souza CP, et al. Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario. Int J Atheroscler 2007;2:189-94
   Google Scholar
• Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus “usual” care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220-8
   PubMed Web of Science ®Google Scholar
• Barrios V, Lobos JM, Serrano A, et al. Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain. J Med Econ 2012;15(Suppl1):45-54
   Google Scholar
• Bennett K, Kabir Z, Barry M, et al. Cost-effectiveness of treatments reducing coronary heart disease mortality in Ireland, 2000 to 2010. Value Health J Int Soc Pharmacoecon Outcomes Res 2009;12:10-15
   Web of Science ®Google Scholar
• Berto P, Munro V, Gaddi A, et al. Cost-effectiveness analysis for statin therapies in the primary prevention of coronary heart disease in Italy. Clin Drug Investig 2000;20:109-21
   PubMed Web of Science ®Google Scholar
• Brandle M, Davidson MB, Schriger DL, et al. Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. Diabetes Care 2003;26:1796-801
   PubMed Web of Science ®Google Scholar
• Buller N, Gillen D, Casciano R, et al. A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom. PharmacoEconomics 2003;21(Suppl 1):25-32
   PubMed Web of Science ®Google Scholar
• Casciano R, Tarride J-E, Breton MC, et al. A pharmacoeconomic evaluation of the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study in Canada. Can J Clin Pharmacol J Can Pharmacol Clin 2004;11:e179-90
   PubMedGoogle Scholar
• CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287:2542-51
   PubMed Web of Science ®Google Scholar
• Chan PS, Nallamothu BK, Gurm HS, et al. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation 2007;115:2398-409
   PubMed Web of Science ®Google Scholar
• Chau J, Cheung BM, McGhee SM, et al. Cost-effectiveness analysis of applying the Cholesterol and Recurrent Events (CARE) study protocol in Hong Kong. Hong Kong Med J Xianggang Yi Xue Za Zhi 2001;7:360-8
   PubMedGoogle Scholar
• Conly J, Clement F, Tonelli M, et al. Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk. CMAJ Can Med Assoc J J Assoc Medicale Can 2011;183:E1180-8
   PubMed Web of Science ®Google Scholar
• Cook JR, Yin D, Alemao E, et al. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway. PharmacoEconomics 2004;22(Suppl 3):49-61
   PubMed Web of Science ®Google Scholar
• Davies A, Hutton J, O’Donnell J, et al. Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK. Br J Cardiol 2006;13:196-202
   Google Scholar
• Delea TE, Jacobson TA, Serruys PW, et al. Cost-effectiveness of fluvastatin following successful first percutaneous coronary intervention. Ann Pharmacother 2005;39:610-16
   PubMed Web of Science ®Google Scholar
• de Vries FM, Denig P, Visser ST, et al. Cost-effectiveness of statins for primary prevention in patients newly siagnosed with type 2 diabetes in The Netherlands. Value Health 2014;17:223-30
   PubMed Web of Science ®Google Scholar
• Erickson KF, Japa S, Owens DK, et al. Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease. J Am Coll Cardiol 2013;61:1250-8
   PubMed Web of Science ®Google Scholar
• Feher MD, Langley-Hawthorne CE, Byrne CD. Cost-outcome benefits of fibrate therapy in type 2 diabetes. Br J Diabetes Vasc Dis 2003;3:124-30
   Google Scholar
• Fidan D, Unal B, Critchley J, et al. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000–2010. QJM 2007;100:277-89
   PubMed Web of Science ®Google Scholar
• Fragoulakis V, Kourlaba G, Maniadakis N. Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece. Clin Outcomes Res CEOR 2012;4:135-43
   PubMedGoogle Scholar
• Franco OH, der Kinderen AJ, De Laet C, et al. Primary prevention of cardiovascular disease: cost-effectiveness comparison. Int J Technol Assess Health Care 2007;23:71-9
   PubMed Web of Science ®Google Scholar
• Gandhi S, Gandhi S, Fox K, et al. Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events. Clin Outcomes Res 2012;4:1-11
   PubMedGoogle Scholar
• Ganz DA, Kuntz KM, Jacobson GA, et al. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med 2000;132:780-7
   PubMed Web of Science ®Google Scholar
• Glasziou PP, Eckermann SD, Mulray SE, et al. Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective? Med J Aust 2002;177:428-34
   PubMed Web of Science ®Google Scholar
• Gómez-Gerique JA, Casciano R, Stern L, et al. A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain. Eur J Health Econ HEPAC Health Econ Prev Care 2004;5:278-84
   PubMedGoogle Scholar
• Greving J, Visseren F, de Wit G, et al. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ 2011;342:d1672
   PubMed Web of Science ®Google Scholar
• Grover SA, Coupal L, Zowall H, et al. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001;24:45-50
   PubMed Web of Science ®Google Scholar
• Grover SA, Coupal L, Zowall H, et al. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: who should be treated? Circulation 2000;102:722-7
   PubMed Web of Science ®Google Scholar
• Grover S, Coupal L, Lowensteyn I. Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective? Can J Cardiol 2008;24:891-8
   Web of Science ®Google Scholar
• Grover SA, Ho V, Lavoie F, et al. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins? Arch Intern Med 2003;163:333-9
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20 536 people. BMJ 2006;333:1145
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. Statin cost-effectiveness in the United States for people at different vascular risk levels. Circ Cardiovasc Qual Outcomes 2009;2:65-72
   PubMed Web of Science ®Google Scholar
• Herregods M-C, Daubresse J-C, Michel G, et al. Discovery Belux: comparison of rosuvastatin with atorvastatin in hypercholesterolaemia. Acta Cardiol 2008;63:493-9
   PubMed Web of Science ®Google Scholar
• Kang H-Y, Ko S-K, Liew D. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: The Korean Individual-Microsimulation Model for Cardiovascular Health Interventions. Clin Ther 2009;31:2919-30
   PubMed Web of Science ®Google Scholar
• Khoury H, Wagner M, Merikle E, et al. Cost-effectiveness of atorvastatin in the primary prevention of major cardiovascular events in patients with type 2 diabetes in Canada. Can J Diabetes 2009;33:363-74
   Google Scholar
• Kohli M, Attard C, Lam A, et al. Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada. PharmacoEconomics 2006;24:815-30
   PubMed Web of Science ®Google Scholar
• Kongnakorn T, Ward A, Roberts CS, et al. Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial. Value Health 2009;12:880-7
   PubMed Web of Science ®Google Scholar
• Lafuma A, Colin X, Solesse A. Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: A French adaptation of CARDS. Arch Cardiovasc Dis 2008;101:327-32
   PubMed Web of Science ®Google Scholar
• Laires PA, Ejzykowicz F, Hsu T-Y, et al. Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal. J Med Econ 2015;18:565-72
   PubMed Web of Science ®Google Scholar
• Liew D, Park H-J, Ko S-K. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea. Clin Ther 2009;31:2189-203
   PubMed Web of Science ®Google Scholar
• Lim SS, Vos T, Peeters A, et al. Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria. Med J Aust 2001;175:459-64
   PubMed Web of Science ®Google Scholar
• Lindgren P, Graff J, Olsson AG, et al. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. Eur Heart J 2006;28:1448-53
   Web of Science ®Google Scholar
• Lindgren P, Buxton M, Kahan T, et al. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial–lipid-lowering arm (ASCOT-LLA). Eur J Cardiovasc Prev Rehabil Off J Eur Soc Cardiol Work Groups Epidemiol Prev Card Rehabil Exerc Physiol 2005;12:29-36
   PubMed Web of Science ®Google Scholar
• Lorgelly PK, Briggs AH, Wedel H, et al. An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. Eur J Heart Fail 2010;12:66-74
   PubMed Web of Science ®Google Scholar
• MacDonald GP. Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein. J Am Osteopath Assoc 2010;110:427-36
   PubMedGoogle Scholar
• Mark DB, Knight JD, Cowper PA, et al. Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: Results from the Treating to New Targets (TNT) Trial. Am Heart J 2008;156:698-705
   PubMed Web of Science ®Google Scholar
• Marshall T. Coronary heart disease prevention: insights from modelling incremental cost effectiveness. BMJ 2003;327:1264
   PubMed Web of Science ®Google Scholar
• Marshall T. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study. Eur J Cardiovasc Prev Rehabil Off J Eur. Soc Cardiol Work Groups Epidemiol Prev Card Rehabil Exerc Physiol 2006;13:523-8
   PubMedGoogle Scholar
• McConnachie A, Walker A, Robertson M, et al. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. Eur Heart J 2014;35:290-8
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20 536 individuals. The Lancet 21;365:1779–85
   Google Scholar
• Mihaylova B, Schlackow I, Herrington W, et al. Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: results of the Study of Heart and Renal Protection (SHARP). Am J Kidney Dis 2016;67:576-84
   PubMed Web of Science ®Google Scholar
• Mould-Quevedo JF, Gutiérrez-Ardila MV, Ordóñez Molina JE, et al. Cost-effectiveness analysis of atorvastatin versus rosuvastatin in primary and secondary cardiovascular prevention populations in Brazil and Columbia. Value Health Reg Issues 2014;5:48-57
   Google Scholar
• Mullins CD, Rattinger GB, Kuznik A, et al. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study. Clin Ther 2008;30(Pt2):2204-16
   Web of Science ®Google Scholar
• Nagata-Kobayashi S, Shimbo T, Matsui K, et al. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan. Int J Cardiol 2005;104:213-23
   PubMed Web of Science ®Google Scholar
• Nash A, Barry M, Walshe V. Cost effectiveness of statin therapy for the primary prevention of coronary heart disease in Ireland. Ir Med J 2006;99:144-5
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia [Internet]. Technol Apprais Guid TA385. 2016. https://www.nice.org.uk/guidance/ta385 11 April 2017
   Google Scholar
• Nherera L, Calvert NW, DeMott K, et al. Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia. Curr Med Res Opin 2010;26:529-36
   PubMed Web of Science ®Google Scholar
• Ohsfeldt RL, Gandhi SK, Smolen LJ, et al. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. J Med Econ 2010;13:428-37
   PubMedGoogle Scholar
• Ohsfeldt RL, Olsson AG, Jensen MM, et al. Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial. J Med Econ 2012;15:125-33
   PubMedGoogle Scholar
• Olsson A, Casciano R, Stern L, et al. A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden. Int J Cardiol 2004;96:51-7
   PubMed Web of Science ®Google Scholar
• Onishi Y, Hinotsu S, Nakao YM, et al. Economic evaluation of pravastatin for primary prevention of coronary srtery disease based on risk prediction from JALS-ECC in Japan. Value Health Reg Issues 2013;2:5-12
   Google Scholar
• Peura P, Martikainen J, Soini E, et al. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. Curr Med Res Opin 2008;24:1823-32
   PubMed Web of Science ®Google Scholar
• Pharmaceutical Benefits Advisory Committee. Public summary document: Ezetimibe with simvastatin tablet, 10 mg–20 mg, Vytorin®. Commonwealth of Australia PBAC; 2009
   Google Scholar
• Pharmaceutical Benefits Advisory Committee. Review of statin therapies. Commonwealth of Australia PBAC; 2012
   Google Scholar
• Pharmaceutical Benefits Advisory Committee. Public summary document: Ezetimibe with simvastatin, tablet, 10 mg–20 mg, Vytorin®. Commonwealth of Australia PBAC; 2012
   Google Scholar
• Pilote L, Ho V, Lavoie F, et al. Cost-effectiveness of lipid-lowering treatment according to lipid level. Can J Cardiol 2005;21:681-7
   PubMed Web of Science ®Google Scholar
• Pinto CG, Carrageta MO, Miguel LS. Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal. Value Health 2008;11:154-9
   PubMed Web of Science ®Google Scholar
• Prosser LA, Stinnett AA, Goldman PA, et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 2000;132:769-79
   PubMed Web of Science ®Google Scholar
• Raikou M, McGuire A, Colhoun HM, et al. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2007;50:733-40
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Clarke LD, Roberts CS, et al. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes. PharmacoEconomics 2008;26:329-39
   PubMed Web of Science ®Google Scholar
• Reckless J, Davies G, Tunceli K, et al. Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study. Value Health 2010;13:726-34
   PubMed Web of Science ®Google Scholar
• Robberstad B, Hemed Y, Norheim OF. Cost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country—the case of Tanzania. Cost Eff Resour Alloc CE 2007;5:3
   PubMedGoogle Scholar
• Rosen VM, Taylor DCA, Parekh H, et al. Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US. PharmacoEconomics 2010;28:47-60
   PubMed Web of Science ®Google Scholar
• Rubinstein A, Colantonio L, Bardach A, et al. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina. BMC Public Health 2010;10:627
   PubMed Web of Science ®Google Scholar
• Rubinstein A, García Martí S, Souto A, et al. Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina. Cost Eff Resour Alloc 2009;7:10
   PubMedGoogle Scholar
• Russell MW, Huse DM, Miller JD, et al. Cost effectiveness of HMG-CoA reductase inhibition in Canada. Can J Clin Pharmacol J Can Pharmacol Clin 2001;8:9-16
   PubMedGoogle Scholar
• Schwartz GG, Ganz P, Waters D, et al. Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. Am J Cardiol 2003;92:1109-12
   PubMed Web of Science ®Google Scholar
• Scottish Medicines Consortium. ADVICE: rosuvastatin, 5 mg, 10 mg, 20 mg, film-coated tablets (Crestor^®) SMC No. (725/11). Glasgow, Scotland: SMC; 2011
   Google Scholar
• Scuffham PA, Chaplin S. An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK. PharmacoEconomics 2004;22:525-35
   PubMed Web of Science ®Google Scholar
• Scuffham PA, Chaplin S. A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful percutaneous coronary intervention. Clin Ther 2005;27:1467-77
   PubMed Web of Science ®Google Scholar
• Scuffham PA, Kósa J. The cost-effectiveness of fluvastatin in Hungary following successful percutaneous coronary intervention. Cardiovasc Drugs Ther 2006;20:309-17
   PubMed Web of Science ®Google Scholar
• Sigvant B, Henriksson M, Lundin F, et al. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective? Eur J Cardiovasc Prev Rehabil 2011;18:254-61
   PubMedGoogle Scholar
• Slejko JF, Page RL, Sullivan PW. Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER. Curr Med Res Opin 2010;26:2485-97
   PubMed Web of Science ®Google Scholar
• Soini EJO, Davies G, Martikainen JA, et al. Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. Curr Med Res Opin 2010;26:25-36
   PubMed Web of Science ®Google Scholar
• Straka RJ, Mamdani M, Damen J, et al. Economic impacts attributable to the early clinical benefit of atorvastatin therapy – a US managed care perspective. Curr Med Res Opin 2007;23:1517-29
   PubMed Web of Science ®Google Scholar
• Taylor DCA, Pandya A, Thompson D, et al. Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study. Eur J Health Econ 2009;10:255-65
   PubMed Web of Science ®Google Scholar
• Tonkin AM, Eckermann S, White H, et al. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: Results from the LIPID study. Am Heart J 2006;151:1305-12
   PubMed Web of Science ®Google Scholar
• Tsevat J, Kuntz KM, Orav EJ, et al. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 2001;141:727-34
   PubMed Web of Science ®Google Scholar
• van Hout B. Cost-effectiveness of HMG coenzyme reductase inhibitors. Whom to treat? Eur Heart J 2001;22:751-61
   PubMed Web of Science ®Google Scholar
• van Nooten F, Davies GM, Jukema JW, et al. Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia. Neth Heart J 2011;19:61-7
   PubMed Web of Science ®Google Scholar
• Wagner M, Lindgren P, Merikle E, et al. Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial. Can J Cardiol 2009;25:e362-9
   Web of Science ®Google Scholar
• Wagner M, Goetghebeur M, Merikle E, et al. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada. Can J Clin Pharmacol J Can Pharmacol Clin 2009;16:e331-45
   PubMedGoogle Scholar
• Walshe V, Nash A, Barry M. Cost effectiveness of statin therapy for primary prevention of coronary heart disease. Ir Med J 2006;100:144-5
   Google Scholar
• Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess Winch Engl 2007;11:1-160, iii-iv
   Web of Science ®Google Scholar
• Zechmeister I, Stollenwerk B, Ara R, et al. Statins for the secondary prevention of cardiovascular diseases: An analysis of expected health gains and cost-utility in Austria. HTA Project Report; Vienna, Austria: Ludwig Boltzmann Gesellschaft GmbH 2008
   Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. The Lancet 2015;385:1397-405
   PubMed Web of Science ®Google Scholar
• Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57
   PubMed Web of Science ®Google Scholar
• Miettinen TA, Pyörälä K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997;96:4211-18
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet Lond Engl 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45
   PubMed Web of Science ®Google Scholar
• Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage J, Bowman L, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet Lond Engl 2010;376:1658-69
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97
   PubMed Web of Science ®Google Scholar
• Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health 2003;6:9-17
   PubMed Web of Science ®Google Scholar